Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
This study is currently recruiting participants.
Verified February 2013 by Eisai Inc.
Study NCT01126749
Information provided by Eisai Inc.
First Received on May 17, 2010.
Last Updated on February 27, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
